MCMCB Pro
J9183

J9183Gemcitabine intravesical system, 225 mg

HCPCSActiveBETOS O1D

J9183 is a HCPCS Level II code for gemcitabine intravesical system, 225 mg. It belongs to the Drugs Administered Other Than Oral Method section. Whether Medicare pays it depends on the coverage rule below.

Medicare coverage: Carrier judgment

Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.

From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.

Physician fee schedule statusE

Excluded from the physician fee schedule by regulation. Payment, where it exists, comes from another fee schedule (drugs via ASP, supplies via DMEPOS, and so on).

Global period: XXX

Want the dollar amount for your locality? The fee calculator applies your GPCI and the current conversion factor.

The CMS record for J9183

Long descriptor
Gemcitabine intravesical system, 225 mg

The official wording. This is what the code means.

Short descriptor
Gemcitabine intravesical sys

CMS's 28-character form, which is what shows up on a remittance advice.

Added
April 1, 2026

When CMS introduced the code.

BETOS
O1D

Berenson-Eggers Type of Service — CMS's own analytic grouping.

Pricing indicator
51 — Other

Drugs.

Codes adjacent to J9183

HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If J9183 is not quite right, the correct code is very often within a few positions of it.

  • J9173Injection, durvalumab, 10 mg
  • J9174Injection, docetaxel (beizray), 1 mg
  • J9175Injection, elliotts' b solution, 1 ml
  • J9176Injection, elotuzumab, 1 mg
  • J9177Injection, enfortumab vedotin-ejfv, 0.25 mg
  • J9178Injection, epirubicin hcl, 2 mg
  • J9179Injection, eribulin mesylate, 0.1 mg
  • J9181Injection, etoposide, 10 mg
  • J9184Injection, gemcitabine hydrochloride (avyxa), 200 mg
  • J9185Injection, fludarabine phosphate, 50 mg
  • J9190Injection, fluorouracil, 500 mg
  • J9196Injection, gemcitabine hydrochloride (accord), not therapeutically equivalent to j9201, 200 mg
  • J9198Injection, gemcitabine hydrochloride, (infugem), 100 mg
  • J9199Injection, gemcitabine hydrochloride (infugem), 200 mgterminated
  • J9200Injection, floxuridine, 500 mg
  • J9201Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg

Questions about J9183

What is HCPCS code J9183?

J9183 is a HCPCS Level II code for gemcitabine intravesical system, 225 mg. It sits in the Drugs Administered Other Than Oral Method section.

Does Medicare cover J9183?

The CMS HCPCS file marks J9183 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.

How is J9183 paid under the physician fee schedule?

J9183 carries PFS status code E. Excluded from the physician fee schedule by regulation. Payment, where it exists, comes from another fee schedule (drugs via ASP, supplies via DMEPOS, and so on).

HCPCS Level II2026Q3-Jul· effective July 1, 2026